FINAL SCIENTIFIC PROGRAMME

Presentation: F. Cognetti

09.00 Lecture: Cancer and Global Health (S. Vella)

Presenting: P. Giacomini

09.20 Lecture: Precision medicine in breast cancer today (D.B. Solit)

Session 1

Her2 positive Tumors

Chairmen: F. Puglisi, C. Tondini

09.40 Optimizing neoadjuvant and adjuvant treatment related to new biology concepts (G. Curigliano)

10.10 When do you add an endocrine drug to the Her2 dual blockade? (G. Arpino)

10.30 Treatment duration of HER2-directed agents in metastatic disease (E. Perez)

10.50 Drug resistance: mechanism and clinical results (M. Scaltriti)

11.10 The use of biosimilars (R. Danesi)

11.30 Open Coffee

11.30 Discussion

Session 2

Luminal Tumors

Chairmen: C. Botti, S. Gori

11.45 The intestinal microbiome (F. Scaldaferri)

12.05 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (M. Cristofanilli)

12.25 New PI3K inhibitors (G. Curigliano)

12.45 Discussion
13.00 Lunch

Session 3
Triple negative
Chairmen: G. Mustacchi, G. Naso

13.45 Insights into the biology: new molecular classification for identifying immuno therapeutics targets (K. Willard-Gallo)

14.05 New Developments in the Treatment of advanced diseases and biomarkers evidence (Michael J. Duffy)

14.25 Neo/adjuvant systemic therapy today (M. Cristofanilli)

14.45 Discussion

Session 4
BRCA and new opinions
Chairmen: S. Cinieri, L. Del Mastro

Presenting: R. Masetti

15.00 Surgical update in patients with early disease and BRCA mutation (V. Sacchini)

15.20 Novel drugs and new trials in BRCA mutated patients (J. Crown)

15.40 Fertility and BRCA mutation (M. Lambertini)

16.00 Discussion

Session 5
Immunosystem and immunotherapy
Chairmen: S. De Placido, E. Bria

16.10 Lecture: Immunotherapy: what we still need to know? (E. Perez)

16.30 New immunotargets in breast cancer (G. Bianchini)

16.50 The combination with nanoparticle molecules (M. De Laurentiis)
17.10 Discussion

Session 6
New Concepts
Chairmen: C. Boni, E. Bria

17.20 From phase I-III to new clinical trials methodologies in breast cancer (P. Bruzzi)

17.40 Clinical utility of multigene assays and outcome of disease (M. De Laurentiis)

18.00 Discussion

10 November

Presenting: F. Cognetti

09.00 Lecture: Breast cancer chemo-prevention (A. De Censi)

Session 7
Supportive care and lifestyle
Chairmen: V. Adamo, C. Nisticò, F. Roila

09.20 Toxicity induced by therapy: the new profile of the oncologist (D. Santini)

09.40 Musculoskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (C.L. Loprinzi)

10.00 Low-fat diet: is it really a predictor for the best outcome? (R.T. Chlebowsky)

10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (D.C. McKenzie)

Presenting: P. Pronzato


11.00 Open Coffee

11.00 Discussion
Session 8
Evolving molecules
Chairmen: G. Ferretti, V. Guarneri

11.20 Etirinotecal pegol: in which position in the future clinical choice? (C.J. Twelves)

11.40 Trop-2: potential target for antibody-drug conjugates (A. Bardia)

12.00 Discussion

Session 9
Hormonal therapy and novel discoveries in drug resistances
Chairmen: A. Fabi, V. Lorusso

12.10 Lecture: Mechanism and clinical results in ER positive patients (A. Di Leo)

12.30 New selective estrogen receptor antagonist (R. Finn)

12.50 Discussion

Session 10
Age and breast cancer
Chairmen: A. Gennari, U. Tirelli

13.00 Evaluation and treatment of older patients (in early stage) (L. Repetto)

13.20 The treatment of Metastatic disease in elderly patients, light and shadow (C. Fontanella)

13.40 Discussion and Conclusions

14.00 Lunch